DK3151831T3 - Priming af kræftceller med lav dosis af naltrexon - Google Patents

Priming af kræftceller med lav dosis af naltrexon Download PDF

Info

Publication number
DK3151831T3
DK3151831T3 DK15730526.9T DK15730526T DK3151831T3 DK 3151831 T3 DK3151831 T3 DK 3151831T3 DK 15730526 T DK15730526 T DK 15730526T DK 3151831 T3 DK3151831 T3 DK 3151831T3
Authority
DK
Denmark
Prior art keywords
naltrexon
priming
low dosage
cancel cells
cancel
Prior art date
Application number
DK15730526.9T
Other languages
Danish (da)
English (en)
Inventor
Angus Dalgleish
Wai Liu
Original Assignee
Cancer Vaccine Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Vaccine Inst filed Critical Cancer Vaccine Inst
Application granted granted Critical
Publication of DK3151831T3 publication Critical patent/DK3151831T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK15730526.9T 2014-06-09 2015-06-09 Priming af kræftceller med lav dosis af naltrexon DK3151831T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1410216.4A GB201410216D0 (en) 2014-06-09 2014-06-09 Therapeutic
PCT/GB2015/051686 WO2015189597A1 (en) 2014-06-09 2015-06-09 Priming of cancer cells with low dose naltrexone

Publications (1)

Publication Number Publication Date
DK3151831T3 true DK3151831T3 (da) 2019-06-24

Family

ID=51266919

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15730526.9T DK3151831T3 (da) 2014-06-09 2015-06-09 Priming af kræftceller med lav dosis af naltrexon

Country Status (10)

Country Link
US (3) US11065245B2 (enExample)
EP (1) EP3151831B1 (enExample)
JP (1) JP6620338B2 (enExample)
DK (1) DK3151831T3 (enExample)
ES (1) ES2730348T3 (enExample)
GB (1) GB201410216D0 (enExample)
PL (1) PL3151831T3 (enExample)
PT (1) PT3151831T (enExample)
TR (1) TR201908660T4 (enExample)
WO (1) WO2015189597A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201308440D0 (en) * 2013-05-10 2013-06-19 Dalgleish Angus Therapeutic
EP3416619A2 (en) * 2016-02-18 2018-12-26 Immune Therapeutics, Inc. Method for inducing a sustained immune response
GB201704909D0 (en) 2017-03-28 2017-05-10 Ldn Pharma Ltd Cancer therapy
GB201704911D0 (en) * 2017-03-28 2017-05-10 Ldn Pharma Ltd High dose combo I
GB201704913D0 (en) 2017-03-28 2017-05-10 Ldn Pharma Ltd Method
EP3482751A1 (en) 2017-11-14 2019-05-15 LDN Pharma Limited Cancer treatment
JP7502320B2 (ja) * 2019-03-06 2024-06-18 エルディーエヌ ファーマ リミテッド 効力を判定するための方法
WO2020178446A1 (en) * 2019-03-06 2020-09-10 LDN Pharma Limited Method of monitoring treatment
GB201903546D0 (en) * 2019-03-15 2019-05-01 Ldn Pharma Ltd Cancer treatment
JP2022541452A (ja) 2019-07-15 2022-09-26 ロバクサ がんの治療のための方法および組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030144312A1 (en) * 2001-10-30 2003-07-31 Schoenhard Grant L. Inhibitors of ABC drug transporters in multidrug resistant cancer cells
CA2719134C (en) 2008-03-21 2015-06-30 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
JP2015107918A (ja) 2012-02-14 2015-06-11 国立研究開発法人国立がん研究センター 抗がん剤の作用を増強する医薬組成物、がん治療用キット、診断薬、及びスクリーニング方法
GB201308440D0 (en) * 2013-05-10 2013-06-19 Dalgleish Angus Therapeutic

Also Published As

Publication number Publication date
PT3151831T (pt) 2019-06-18
JP6620338B2 (ja) 2019-12-18
PL3151831T3 (pl) 2021-05-31
GB201410216D0 (en) 2014-07-23
US20250032481A1 (en) 2025-01-30
US20170119755A1 (en) 2017-05-04
EP3151831B1 (en) 2019-03-13
TR201908660T4 (en) 2019-07-22
US12144807B2 (en) 2024-11-19
EP3151831A1 (en) 2017-04-12
US20210308125A1 (en) 2021-10-07
WO2015189597A1 (en) 2015-12-17
JP2017519006A (ja) 2017-07-13
US11065245B2 (en) 2021-07-20
ES2730348T3 (es) 2019-11-11

Similar Documents

Publication Publication Date Title
IL280905A (en) Methods of modulating drug plasma levels using erythrohydroxybupropion
DK3302565T3 (da) Faste doseringsformer af palbociclib
DK3119397T3 (da) Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser
DK3851537T3 (da) Behandling af hyperbilirubinæmi
DK3356358T3 (da) Mikrobiocide oxadiazolderivater
DK3148625T3 (da) Opklappelig kateterpakning
DK3521282T3 (da) Quinazolinderivater anvendt til behandling af hiv
HUE037587T2 (hu) Önálló fecskendõcsatlakozás
DK3137169T3 (da) Hæmmere af lysin-specifik demethylase-1
DK3125875T3 (da) Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande
DK3157508T3 (da) Fast oral doseringsform af lipofile forbindelser
DK3185853T3 (da) Inhalerbare pulverformuleringer af alginatoligomerer
DK3116491T3 (da) Farmaceutiske sammensætninger af terapeutisk aktive forbindelser
DK3107366T3 (da) Priming af frø
DK3099298T3 (da) Kombinationsterapier med zidovudin til behandling af mikrobielle infektioner
DK3297653T3 (da) Behandling af postbariatrisk hypoglykæmi med glp-1-antagonister
IL242971B (en) Ventricular far field reduction
DK3294283T3 (da) Sacubitril-valsartan-doseringsregime til behandling af hjerteinsufficiens
DK4008329T3 (da) Isoxazolinforbindelser til anvendelse i behandling af demodicose
DK3164123T3 (da) Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier
DK3171700T3 (da) Infusionsanlæg
DK3204038T3 (da) Sammensætninger omfattende amylase til anvendelse i behandlingen af pruritus
DK3363428T3 (da) Perfusionsdoseringsform
DK3094322T3 (da) Administration af tasimelteon i fastende tilstand
HRP20181570T1 (hr) Režim doziranja spoja fgf-18